Solid Biosciences Inc. SLDB
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- +6.21%
- 1 year
- +11.13%
- Open
- 6.24
- Prev close
- 6.20
- Mkt cap
- 642.82M
- Vol
- 191.98K
- Avg vol
- 1.18M
- EPS
- -1.89
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.98
- High
- 6.31
- Forward P/E
- -5.46
- Beta
- 2.44
- Short ratio
- 17.18
- Inst. own
- 107.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 9.32
- 200-d avg
- 7.34
- 1y target
- 18.67
News
-
1 week ago benzinga.com
Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a…
1 week ago globenewswire.com
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a…
1 week ago defenseworld.net
Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Monday
Solid Biosciences (NASDAQ: SLDB - Get Free Report) is projected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of…
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
1 month ago benzinga.com
This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.
-
1 month ago benzinga.com
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $25 price target.
2 months ago benzinga.com
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva…
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $16 to $20.
2 months ago benzinga.com
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
-
2 months ago benzinga.com
Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 9.52 percent increase over losses of…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25
HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target
Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $16 price target.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16
Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $16.
-
5 months ago benzinga.com
Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18
Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $17 to $18.
-
5 months ago benzinga.com
Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.44) by 18.18 percent. This is a 11.86 percent increase over losses of…
-
5 months ago benzinga.com
Solid Biosciences Doses First Participant In Phase 3 IMPACT DUCHENNE Clinical Trial For SGT-003 In Duchenne Muscular Dystrophy
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global…
-
6 months ago benzinga.com
Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy -…
-
7 months ago benzinga.com
JP Morgan Maintains Overweight on Solid Biosciences, Raises Price Target to $12
JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $11 to $12.
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $20 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $20 price target.
7 months ago benzinga.com
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
-
7 months ago benzinga.com
Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.
-
7 months ago benzinga.com
Solid Biosciences Q4 EPS $(0.53) Misses $(0.50) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.50) by 5.79 percent. This is a 47 percent increase over losses of…
-
7 months ago benzinga.com
Wedbush Maintains Outperform on Solid Biosciences, Raises Price Target to $17
Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and raises the price target from $14 to $17.
7 months ago benzinga.com
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned
Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.
-
7 months ago benzinga.com
Solid Biosciences' SGT-003 Shows Robust Microdystrophin Expression, DAPC Restoration, Cardiac Function Improvements And Encouraging Safety Profile In 40 INSPIRE DUCHENNE Participants; Plans For Additional Meetings With The FDA In H1 2026
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -- Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex…
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on Solid Biosciences, Maintains $14 Price Target
Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $14 price target.
7 months ago benzinga.com
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
7 months ago benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago benzinga.com
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.
-
8 months ago benzinga.com
Solid Biosciences To Raise ~$240M Via Private Placement, Closing Expected March 9
Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities…
-
8 months ago benzinga.com
Solid Biosciences Presents SGT-003, Next-Gen Investigational Gene Therapy For Duchenne Muscular Dystrophy, And SGT-212, Dual-Route Investigational Gene Therapy For FA At 2026 MDA Clinical & Scientific Conference
Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its…
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
8 months ago benzinga.com
Solid Biosciences Announces Positive Regulatory Update From Type C Meeting With FDA Supporting Continued Advancement Of SGT-003 As Potential Treatment For Duchenne Muscular Dystrophy
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 -- Company…
-
9 months ago benzinga.com
Solid Biosciences Expects Patient Dosing In Q1 In IMPACT DUCHENNE Trial, Additional Data Anticipated For hase 1/2 INSPIRE DUCHENNE Study In Mid-2026
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will provide a corporate…
-
9 months ago benzinga.com
Solid Biosciences' SGT-212 Secures FDA Orphan Drug, Fast Track And Rare Pediatric Disease Designations; First Patient Dosed In Phase 1b FALCON Trial, Initial Data Expected H2 2026
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data…
-
9 months ago benzinga.com
FDA Grants Solid Biosciences Orphan Drug Designation For SGT-212 For Friedreich's Ataxia
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data…
-
10 months ago benzinga.com
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
11 months ago benzinga.com
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst
Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.
11 months ago benzinga.com
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
11 months ago benzinga.com
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
1 year ago benzinga.com
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket